2 news items
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing's Syndrome)
CORT
28 May 24
statements based on our current plans and expectations that are subject to risks and uncertainties that might cause our actual results to differ materially
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
CORT
8 Apr 24
based on our current plans and expectations that are subject to risks and uncertainties that might cause our actual results to differ materially from
- Prev
- 1
- Next